Combined oral contraceptives

New Data Show NEXTSTELLIS® Has Selective Impact On Endocrine Markers Compared With Common Combined Oral Contraceptives

Retrieved on: 
Saturday, March 6, 2021
Steroids, Drugs, Sex hormones, Combined oral contraceptives, Estrogens, Hormonal contraception, Estranes, Phenols, Estetrol/drospirenone, Estetrol, Drospirenone, DRSP

"Based on our findings, treatment with DRSP/E4 has limited effects on some of these endocrine parameters compared to the tested EE-containing products, giving DRSP/E4 a different and potentially favorable endocrine profile compared to those EE-based COCs."

Key Points: 
  • "Based on our findings, treatment with DRSP/E4 has limited effects on some of these endocrine parameters compared to the tested EE-containing products, giving DRSP/E4 a different and potentially favorable endocrine profile compared to those EE-based COCs."
  • Comparative findings include:
    A significant increase in sex hormone-binding globulin (SHBG) was observed at cycle 3 (240%) and 6 (251%) with DRSP/EE as compared to baseline or those observed with NEXTSTELLIS (52% and 55%).
  • At cycle 6, NEXTSTELLIS had a significantly lower impact on dehydroepiandrosterone sulfate (DHEA-S) levels than DRSP/EE (10% vs. 27%).
  • Developed by Mayne Pharma's development and manufacturing partner Mithra Pharmaceuticals SA, NEXTSTELLIS is a novel, investigational combined oral contraceptive pill containing 3 mg drospirenone (DRSP) and 15 mg estetrol (E4).

Mayne Pharma launches another generic oral contraceptive

Retrieved on: 
Thursday, March 4, 2021
Combined oral contraceptives, Drugs, Health care, Ethinylestradiol/etonogestrel, Pharmacology, Combined oral contraceptive pill, Birth control pill formulations, Ortho, Estetrol/drospirenone, Generic drug, Ortho Pharmaceutical

This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.

Key Points: 
  • This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.
  • Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives.
  • Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options.
  • "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS (E4/DRSP) and a generic version of NUVARING.

Study Finds Key Brain Region Smaller in Birth Control Pill Users

Retrieved on: 
Wednesday, December 4, 2019
Birth control, Women's health, Oral contraceptive pill, Combined oral contraceptives, Hepatotoxins, RTT, Drugs, Health

This may be in part because validated methods to quantitatively analyze MRI exams of the hypothalamus have not been available.

Key Points: 
  • This may be in part because validated methods to quantitatively analyze MRI exams of the hypothalamus have not been available.
  • "We validated methods for assessing the volume of the hypothalamus and confirm, for the first time, that current oral contraceptive pill usage is associated with smaller hypothalamic volume."
  • In his study, Dr. Lipton and colleagues recruited a group of 50 healthy women, including 21 women who were taking oral contraceptives.
  • "This initial study shows a strong association and should motivate further investigation into the effects of oral contraceptives on brain structure and their potential impact on brain function."

Global Loestrin 24 Fe- Drug Insights, 2019-2021: MOA, Target, Dosage, Route of Administration, Molecule Type, Strength, Chemical Type and ATC Classification - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 28, 2019
Health, Pharmaceutical, Health, Combined oral contraceptives, Pharmaceutical sciences, Ethinylestradiol/norethisterone acetate, Pharmaceutical industry

The "Loestrin 24 Fe- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Loestrin 24 Fe- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • This pharmaceuticals report, "Loestrin 24 Fe Drug Insight, 2019" highlights the drug marketed details and the Global API Manufacturers details across the globe along with their location.
  • The report covers the Global Market Assessment of the Loestrin 24 Fe covering the historical global sales and also provides the Loestrin 24 Fe sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Loestrin 24 Fe and emerging therapies in this space.

Lyndra Therapeutics to Develop Once-Monthly Oral Contraceptive

Retrieved on: 
Tuesday, July 30, 2019
Biotechnology, Other Health, Health, Pharmaceutical, Progestogens, Drugs, Hepatotoxins, Combined oral contraceptives, Health, Oral contraceptive pill, Combined oral contraceptive pill, Progestin, Birth control, Medication, Medicine, Family planning, Lyndra Therapeutics’ Platform, Lyndra Therapeutics

Currently under consideration as a once-a-month contraceptive, the oral dosage form would provide women with a discreet, non-invasive option to support their family planning.

Key Points: 
  • Currently under consideration as a once-a-month contraceptive, the oral dosage form would provide women with a discreet, non-invasive option to support their family planning.
  • *
    This grant is special because it extends our focus on meeting unmet therapeutic need into womens health, said Amy Schulman, CEO and co-founder of Lyndra Therapeutics.
  • With the funds, Lyndra is currently designing and building a new once-monthly oral combination therapy that delivers a continuous dose of estrogen and progestin, the same drugs used in daily combined oral contraceptives.
  • Lyndra Therapeutics aims to improve healthcare outcomes through oral, ultra-long-acting, sustained-release therapies that change how people take medicines.

Exeltis USA, Inc. Announces the Approval of Slynd™, the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window

Retrieved on: 
Thursday, June 6, 2019
Drugs, Sex hormones, Organic compounds, Progestogens, Hormonal contraception, Hepatotoxins, Pregnanes, Combined oral contraceptives, Combined oral contraceptive pill, Progestin, Oral contraceptive pill, Progesterone

Slynd, a progestin-only pill (POP) is a novel estrogen-free oral contraceptive that is intended as a 24 active with 4 inactive tablet dosing regimen and also allows a 24-hour missed pill window.

Key Points: 
  • Slynd, a progestin-only pill (POP) is a novel estrogen-free oral contraceptive that is intended as a 24 active with 4 inactive tablet dosing regimen and also allows a 24-hour missed pill window.
  • In addition, the safety of Slynd is supported by its approval with no black box warning unlike other combined oral contraceptives.
  • renal impairment, hepatic impairment and adrenal insufficiency), Slynd is contraindicated due to its anti-mineralocorticoid activity.
  • With a geographical footprint spanning over 40 countries, Exeltis employs over 4,000 professionals supported by a global production network.

The global contraceptive market is anticipated to generate revenue of $24.2 billion in 2018 and to grow at a CAGR of 6.96% between 2019 and 2027.

Retrieved on: 
Wednesday, April 24, 2019
Hormonal contraception, Birth control, Women's health, Unintended pregnancy, Oral contraceptive pill, Hepatotoxins, Contents, Combined oral contraceptives, Medical specialties, Birth control in France

The global contraceptive market is anticipated to generate revenue of $24.2 billion in 2018 and to grow at a CAGR of 6.96% between 2019 and 2027.

Key Points: 
  • The global contraceptive market is anticipated to generate revenue of $24.2 billion in 2018 and to grow at a CAGR of 6.96% between 2019 and 2027.
  • The contraceptive drugs comprise of oral contraceptive pills, injectable contraceptives, and topical contraceptives whereas contraceptive devices are male condoms, female condoms, diaphragms, contraceptive sponges, vaginal rings, subdermal implants, and intra-uterine devices.
  • These pills are highly effective drugs used for preventing unwanted and unplanned pregnancy, and for regularizing periods.
  • The main challenge that has been reported in this region is providing sexual health information & services to an inappropriate population.

Global $8.2 Bn Contraceptives Market Opportunity Analysis and Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 28, 2019
Women, Health, Consumer, General Health, Birth control, Women's health, Hepatotoxins, Combined oral contraceptives, Hormonal contraception

The "Contraceptives: Opportunity Analysis and Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contraceptives: Opportunity Analysis and Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering.
  • "Contraceptives: Opportunity Analysis and Forecasts to 2027", states that the launch of four novel contraceptive drug candidates will drive growth of the female contraceptive market over the forecast period.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the contraceptives market.
  • Analysis of the current and future market competition in the global contraceptives market.

Loestrin 24 Fe - API Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 25, 2019
Health, Pharmaceutical, Physical sciences, Chemistry, Combined oral contraceptives, Ethinylestradiol/norethisterone acetate, Application programming interface, Iron, Atoms

The "Loestrin 24 Fe - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Loestrin 24 Fe - API Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Loestrin 24 Fe - API Insight, 2019 provides product and API manufacturers' details across the globe along with the location.
  • The report gives the clear idea on the country wise DMF filed by worldwide companies related to Loestrin 24 Fe.
  • The report also highlights the patent details of Loestrin 24 Fe.